📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-17 15:03
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
16 announcements match the current filters (relevance ≥ 5).
Excel Industries Q1 PAT Drops 13% YoY to ₹29.1 Cr; Completes ₹40 Cr Dedicated Facility
In its Q1 FY27 investor presentation, Excel Industries reported standalone revenue of ₹293.7 crore (down 5.1% YoY) and PAT of ₹29.1 crore (down 13.3% YoY), impacted by erratic monsoon demand in agrochemical intermediates and lower other income. Operating EBITDA remained steady at ₹42.4 crore, with margins expanding 70 bps YoY to 14.4% driven by improved product mix. The company successfully commissioned its ₹40 crore dedicated manufacturing project on July 23, 2026, which backs a 5-year supply agreement with ₹35-40 crore annual revenue potential. Furthermore, a 1,265 MTPA specialty chemical expansion at Lote (₹5 crore capex) is slated for commissioning by February 2027.
Confidence: HIGH
What changedReleased Q1 FY27 earnings presentation and announced the on-time commissioning of a ₹40 crore dedicated contract manufacturing facility.
Why it mattersThe completed facility adds ~₹35-40 crore in high-margin non-agro revenue (~3.5% of TTM revenue), aiding strategic diversification away from monsoon-dependent agrochemicals.
Q1 FY27 Revenue: ₹293.7 CrQ1 FY27 EBITDA Margin: 14.4%Q1 FY27 Standalone PAT: ₹29.1 CrCompleted Project Capex: Rs. 40 croresContract Revenue Potential: Rs. 35-40 Cr p.a.Completed Capex vs TTM Revenue: ~3.7%
📅 Short termAgrochemical intermediate demand remains soft in Q2 FY27, though incremental revenue from the new dedicated plant will begin supporting top-line figures.
📈 Long termExpansion into non-agro specialty chemicals, biocide platforms, and long-term contract manufacturing gradually reduces dependence on cyclical crop cycles.
⚠ Risk flags
- Near-term demand headwinds in the agrochemical intermediates segment.
- Raw material price volatility and ongoing global shipping/logistics disruptions.
Key Highlights
Standalone Q1 FY27 revenue stood at ₹293.7 crore (-5.1% YoY), while EBITDA remained stable at ₹42.4 crore (+0.3% YoY).
Standalone PAT fell 13.3% YoY to ₹29.1 crore, primarily weighed down by lower other income (₹6.2 crore vs ₹11.8 crore).
Successfully completed ₹40 crore dedicated capex on July 23, 2026, targeting ₹35-40 crore annual revenue potential under a 5-year pact.
Capex of ~₹5 crore underway for a 1,265 MTPA specialty chemical facility at Lote, expected to launch in February 2027.
👀 What to Watch
Track the volume ramp-up of the newly commissioned dedicated facility in Q2 FY27 and look for signs of demand revival in agrochemical intermediates.
Q1 Net Profit at 29.1 Cr, Down 13% YoY but Up 129% QoQ
Excel Industries reported a mixed performance for Q1 FY27, with revenue from operations at 293.73 Cr, a 5.1% decline compared to 309.47 Cr in Q1 FY26. Net profit followed a similar YoY trend, falling 13.3% to 29.11 Cr from 33.56 Cr. However, the company showed a significant sequential recovery, with net profit more than doubling from 12.71 Cr in Q4 FY26. The company maintains a strong balance sheet with a debt-to-equity ratio of 0.01 and a net worth of 1,221 Cr.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27, showing a significant sequential profit rebound despite a year-on-year decline in both revenue and profit.
Why it mattersThe results indicate a potential bottoming out of the margin pressure seen in FY26, although the agrochemical sector remains sensitive to monsoon patterns and export headwinds.
Revenue (Q1 FY27): 293.73 CrNet Profit (Q1 FY27): 29.11 CrQoQ Profit Growth: 129%YoY Revenue Growth: -5.1%EPS (Q1 FY27): 23.16Debt-to-Equity Ratio: 0.01
📅 Short termThe strong sequential profit growth may provide short-term support to the stock price, though the YoY decline reflects ongoing industry challenges.
📈 Long termThe company's strategy to expand into non-agro specialty chemicals and biocides is critical for long-term structural growth and reducing dependence on cyclical agrochemical markets.
⚠ Risk flags
- Cyclicality of the agrochemical segment
- Sensitivity to monsoon patterns
- Export market headwinds
Key Highlights
Revenue from operations reached 293.73 Cr, showing a 4.5% sequential growth over Q4 FY26.
Net profit for the quarter stood at 29.11 Cr, a sharp 129% increase from the 12.71 Cr reported in the previous quarter.
Profit Before Tax (PBT) margin was 13.1% for the quarter, compared to 14.3% in the year-ago period.
Total expenses for the quarter were 261.42 Cr, down from 277.02 Cr YoY, aided by lower raw material consumption costs.
Earnings Per Share (EPS) for Q1 FY27 was 23.16, down from 26.70 in Q1 FY26 but up from 10.11 in Q4 FY26.
👀 What to Watch
Investors should monitor the sustainability of the sequential margin recovery and the execution of the planned 35-40 Cr investment in non-agro specialty chemicals to reduce cyclicality.
1265 MTPA Specialty Chemical Capacity Addition at Rs 5.05 Cr Investment
Excel Industries is setting up a new 1265 MTPA facility for a specialty chemical at its Lote site, targeting both domestic and international markets. The project involves a modest investment of Rs 5.05 crore, which will be funded entirely through internal accruals. Commissioning and the subsequent product launch are expected by February 2027. While the investment is small at approximately 0.46% of TTM revenue, it aligns with the company's strategy to diversify its portfolio into non-agro specialty chemicals.
Confidence: HIGH
What changedExcel Industries is expanding its product basket by setting up a dedicated 1265 MTPA manufacturing line for a new specialty chemical at its Lote facility.
Why it mattersThis move is part of the company's strategy to reduce dependence on the cyclical agrochemical sector, which is currently sensitive to monsoon patterns and export headwinds.
Proposed Capacity: 1265 MTPAInvestment Value: Rs 5.05 croreInvestment vs TTM Revenue: 0.46%Expected Launch Date: February 2027TTM Revenue: Rs 1094 Cr
📅 Short termThe announcement is unlikely to trigger significant price movement given the small size of the investment relative to the company's Rs 1145 Cr market cap.
📈 Long termWhile the current investment is small, it represents a continued shift toward non-agro specialty chemicals, which could lead to more stable margins over the long term.
⚠ Risk flags
- Execution risk regarding the February 2027 commissioning timeline
- Market acceptance risk for the new product
Key Highlights
Proposed capacity addition of 1265 MTPA for a new specialty chemical product.
Total investment required is Rs 5.05 crore, to be met through internal accruals.
Project commissioning and product launch targeted for February 2027.
Product intended for both domestic and overseas markets to diversify the portfolio.
👀 What to Watch
Investors should monitor the commissioning timeline in early 2027 and look for management commentary on the margin profile of this new specialty chemical in future earnings calls.
1265 MTPA Capacity Addition for New Specialty Chemical at Rs 5.05 Cr
Excel Industries is expanding its Lote site with a new 1265 MTPA facility dedicated to a specialty chemical, marking a diversification into a new product line. The project involves a modest investment of Rs 5.05 crore, representing approximately 0.46% of TTM revenue, and will be funded entirely through internal accruals. Commissioning and product launch are scheduled for February 2027, targeting both domestic and international markets. This move aligns with the company's stated strategy to reduce its dependence on cyclical agrochemical segments.
Confidence: HIGH
What changedExcel Industries is establishing a new manufacturing line for a specialty chemical at its Lote site, moving from zero existing capacity for this specific product to 1265 MTPA.
Why it mattersThe expansion supports the company's strategic shift toward non-agro specialty chemicals, aiming to mitigate the volatility associated with monsoon-dependent agrochemical cycles and export headwinds.
Proposed Capacity: 1265 MTPAInvestment Required: Rs 5.05 croresInvestment vs TTM Revenue: ~0.46%Investment vs Net Worth: ~0.41%Expected Launch Date: February 2027
📅 Short termThe announcement is likely to be viewed neutrally to slightly positively by the market, as the investment size is small relative to the company's balance sheet but demonstrates ongoing growth initiatives.
📈 Long termStructurally, this adds to the company's 'Performance Solutions' segment, which is key to achieving its 13-15% expected growth rate and reducing sector-specific cyclicality.
⚠ Risk flags
- Execution risk related to the February 2027 commissioning timeline
- Market acceptance risk for the new specialty chemical product
Key Highlights
Proposed capacity addition of 1265 MTPA for a new specialty chemical product
Total investment of Rs 5.05 crore to be funded via internal accruals
Projected commissioning and product launch date set for February 2027
Facility will cater to both domestic and overseas markets to diversify the portfolio
👀 What to Watch
Investors should track the commissioning progress toward the February 2027 deadline and monitor management commentary regarding the revenue potential and margin profile of this new specialty chemical.
Rs 35-40 Cr Annual Income: Excel Industries Completes Capex for 5-Year Supply Contract
Excel Industries has successfully commissioned a dedicated manufacturing facility for a 5-year specialty chemical supply agreement with a leading Indian firm. The project involved a Rs 40 Cr capex and was completed on schedule on July 23, 2026. The contract is expected to generate Rs 35-40 Cr in annual income net of raw material costs, which is highly significant given the company's TTM PAT of Rs 75 Cr. This commissioning marks a strategic shift towards non-agro specialty chemicals and contract manufacturing.
Confidence: HIGH
What changedThe company has transitioned from the construction phase to the production phase for a major long-term supply contract signed in late 2025.
Why it mattersThe projected annual income (net of RM) of ~Rs 37.5 Cr (midpoint) represents nearly 50% of the company's TTM Net Profit, suggesting a potential for significant earnings accretion and margin improvement.
Estimated Capex: Rs 40 CrAnnual Income (Net of RM): Rs 35-40 CrContract Duration: 5 yearsCapex vs Net Worth: 3.3%Income (Net of RM) vs TTM PAT: 50%
📅 Short termThe timely completion of the project is a positive execution signal that may support the stock price in the coming weeks as the market factors in the new revenue stream.
📈 Long termThis project establishes a base for the company's contract manufacturing vertical, potentially leading to a re-rating if it successfully diversifies away from the volatile agrochemical sector.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Customer concentration risk due to a dedicated facility for a single client
- Execution risk in ramping up production to full capacity
Key Highlights
Rs 35-40 Cr annual income (net of raw material costs) expected over a 5-year supply period
Rs 40 Cr capex successfully deployed for a dedicated manufacturing setup
Rs 25 Cr trade advance received from the customer to support project execution
Project completed on July 23, 2026, meeting the original timelines agreed in November 2025
Contract focuses on non-agro specialty chemicals to reduce cyclicality from the core agrochemical business
👀 What to Watch
Watch for the revenue and margin ramp-up in the September 2026 quarterly results to confirm the incremental contribution of this contract to the bottom line.
Rs 40 Cr Capex Completed: Excel Industries Commissions Specialty Chemical Facility
Excel Industries has successfully commissioned a dedicated manufacturing facility for a specialty chemicals contract as of July 23, 2026. The project involved a capital expenditure of approximately Rs 40 Cr, which is roughly 3.3% of the company's net worth. This facility is tied to a long-term contract expected to generate an annual income (net of raw material costs) of Rs 35-40 Cr. This move aligns with the company's strategy to expand its non-agro specialty chemicals portfolio and reduce dependence on cyclical agrochemical markets.
Confidence: HIGH
What changedThe company has transitioned from the investment/construction phase to the operational phase for a major contract manufacturing project.
Why it mattersThe expected annual income (net of RM) of ~Rs 35-40 Cr is significant compared to the TTM PAT of Rs 75 Cr, potentially providing a high-margin revenue stream and diversifying the business away from agrochemicals.
Estimated Capex: Rs 40 CrExpected Annual Income (Net of RM): Rs 35-40 CrCapex vs Net Worth: ~3.3%Income vs TTM PAT: ~47-53%Completion Date: 23rd July 2026
📅 Short termPositive sentiment is expected as the project was completed within the timeline, signaling strong execution capabilities.
📈 Long termThis expansion supports a structural shift toward high-value specialty chemicals, which could improve the company's overall operating margins (currently 10.1%) and reduce earnings volatility.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Client concentration risk for the dedicated facility
- Execution risk in achieving the projected income levels
Key Highlights
Project successfully completed and commissioned on July 23, 2026.
Estimated capital expenditure of ~Rs 40 Cr for the dedicated setup.
Expected annual income (net of raw material cost) of Rs 35-40 Cr from the contract.
The project follows a binding term sheet signed with an Indian Specialty Chemicals Company in November 2025.
The new facility targets the non-agro specialty chemical market to mitigate sector-specific cyclicality.
👀 What to Watch
Monitor the revenue ramp-up and margin contribution from this facility in the Q2 and Q3 FY27 results to validate the projected Rs 35-40 Cr annual income.
Excel Industries Reports 12% Revenue Growth in FY26; Declares ₹13.75 Final Dividend
Excel Industries reported a steady performance for FY26 with revenues reaching ₹1,094 crores, up 11.8% year-on-year, despite a challenging first half for the agrochemical sector. The company's EBITDA for the year stood at ₹112 crores with a 10.1% margin, while the balance sheet remains strong with zero long-term debt. Management highlighted the operationalization of a 2,530 TPA biocide capacity and a new contract manufacturing line expected by July 2026. A final dividend of ₹13.75 per share was declared, reflecting a 275% payout on face value.
Key Highlights
FY26 net operating revenue grew 11.8% YoY to ₹1,094 crores with a PAT of ₹73 crores
Declared a final dividend of ₹13.75 per equity share, representing 275% of the face value
New capacity of 2,530 TPA for biocides became operational in H2 FY26 to drive future volumes
Maintains a strong financial position with zero long-term debt and a net cash surplus
Dedicated contract manufacturing line for a major MNC agreement is on track for July 2026 commissioning
👀 What to Watch
Investors should monitor the successful ramp-up of the new contract manufacturing line in July 2026 and the impact of monsoon patterns on agrochemical demand. While the dividend provides a yield cushion, the company's ability to improve EBITDA margins beyond the current 10% range is critical for long-term re-rating.
Excel Industries FY26 Revenue Up 12% to ₹1,094 Cr; PAT Declines 12% on Margin Pressure
Excel Industries reported a 12% YoY growth in standalone revenue to ₹1,094 Cr for FY26, driven by improved demand for agrochemical intermediates and biocides. However, full-year PAT declined by 12% to ₹73 Cr as adjusted EBITDA margins contracted from 12.3% to 10.1% due to rising input material costs. The Q4 performance showed recovery with revenue and PAT growing 13% and 12% respectively. The company operationalized a new R&D center and remains focused on expanding its biocide portfolio and contract manufacturing projects.
Key Highlights
Standalone revenue for FY26 grew 11.88% to ₹1,094.2 Cr, while Q4 revenue rose 13.4% to ₹281.1 Cr.
Full-year PAT decreased by 12.1% to ₹73.4 Cr as margins were impacted by higher raw material costs.
Adjusted EBITDA margins for FY26 contracted to 10.1% from 12.3% in the previous fiscal year.
Export revenue grew by 26% YoY, contributing 20% (₹223 Cr) to the total revenue in FY26.
Operationalized a new Corporate R&D Center at Rabale, Navi Mumbai, to support long-term product development.
👀 What to Watch
Investors should monitor the company's ability to sustain the Q4 recovery and manage raw material volatility, especially with El Niño risks. The growth in the biocide segment and progress in contract manufacturing remain key long-term triggers.
Excel Industries Recommends Final Dividend of Rs 13.75 Per Share for FY 2025-26
Excel Industries Limited has announced a final dividend of Rs 13.75 per equity share for the financial year ended March 31, 2026. This dividend represents a 275% payout on the face value of Rs 5 per share. The recommendation is subject to shareholder approval at the upcoming Annual General Meeting (AGM). Additionally, the company reported its audited financial results for the full year with an unmodified auditor's opinion from Price Waterhouse.
Key Highlights
Recommended a final dividend of Rs 13.75 per equity share (275% of face value of Rs 5)
Board approved audited standalone and consolidated financial results for the year ended March 31, 2026
Dividend to be paid within 30 days of shareholder approval at the ensuing AGM
Statutory auditors issued an unmodified opinion on the financial results for FY 2025-26
👀 What to Watch
Investors should monitor the announcement of the AGM date and record date to ensure eligibility for the Rs 13.75 per share dividend. The stock remains a watch for those seeking dividend yield in the chemicals and biotech sector.
Excel Industries Recommends Rs 13.75 Dividend and Approves FY26 Audited Financial Results
Excel Industries Limited has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. A key highlight for shareholders is the recommendation of a dividend of Rs. 13.75 per equity share, which is 275% of the face value of Rs. 5. The company's auditors, Price Waterhouse Chartered Accountants LLP, have issued an unmodified opinion, confirming the reliability of the financial statements. The dividend payout is subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended a dividend of Rs. 13.75 (275%) per equity share of face value Rs. 5 for FY 2025-26
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026
Statutory auditors issued an unmodified opinion on the financial results, indicating no major accounting discrepancies
Dividend to be paid within 30 days of approval at the ensuing Annual General Meeting
👀 What to Watch
Investors should view the substantial dividend recommendation as a sign of strong cash flow and management confidence. Existing shareholders should hold for the dividend payout, while potential investors may evaluate the yield based on current market prices.
Excel Industries Board Meeting on May 22, 2026, to Consider FY26 Results and Dividend
Excel Industries Limited has scheduled a Board of Directors meeting for May 22, 2026, to approve the audited financial results for the fiscal year ended March 31, 2026. The board will also evaluate and potentially recommend a dividend for the financial year 2025-26. In compliance with SEBI insider trading regulations, the trading window for insiders will remain closed until May 24, 2026, and will reopen on May 25, 2026. This meeting is a standard regulatory requirement for annual financial reporting and corporate distribution decisions.
Key Highlights
Board meeting scheduled for May 22, 2026, to approve audited FY26 financial results.
Potential dividend recommendation for the financial year 2025-26 will be considered.
Trading window for designated persons remains closed until May 24, 2026.
The announcement follows SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 What to Watch
Investors should monitor the outcome of the May 22 meeting for the company's full-year performance and dividend yield. No immediate action is necessary until the financial data and dividend payout details are released.
Excel Industries Corrects Q2 FY26 EPS from 41.90 to 14.90 Following NSE Query
Excel Industries Limited has issued a clarification regarding a reporting error in its financial results for the quarter ended September 30, 2025. The company admitted that the Earnings Per Share (EPS) was incorrectly stated as 41.90 in the XBRL filing due to an inadvertent error. The actual EPS for the period is 14.90, which is significantly lower than the figure previously recorded in the exchange's digital format. The company has now submitted the corrected XBRL filing to the National Stock Exchange.
Key Highlights
Standalone EPS for the quarter ended September 30, 2025, revised from 41.90 to 14.90
Clarification issued in response to a discrepancy notice from the National Stock Exchange (NSE)
The error was attributed to an inadvertent mistake during the XBRL filing process
Revised XBRL data has been uploaded to the NEAPS portal to reflect the correct financial metrics
👀 What to Watch
Investors should update their financial models to reflect the corrected EPS of 14.90 for the September 2025 quarter. While this is a clerical correction, the significant difference in the figures warrants a more cautious look at the company's internal reporting controls.
Excel Industries Q3 Net Profit Rises 31% YoY to ₹8.40 Cr; Revenue Up 19%
Excel Industries reported a 19% YoY growth in revenue from operations to ₹233.45 crore for the quarter ended December 31, 2025. Net profit for the quarter increased by 31.3% YoY to ₹8.40 crore, showing a recovery from the previous year's quarterly performance. However, for the nine-month period, net profit declined by 15.8% YoY to ₹60.69 crore, indicating some margin pressure earlier in the fiscal year. The company has also reorganized its reporting into a single 'Chemicals' segment and made a one-time provision of ₹1.15 crore for gratuity due to new Labour Codes.
Key Highlights
Quarterly Revenue from operations grew 18.8% YoY to ₹233.45 crore from ₹196.41 crore.
Net Profit for Q3 FY26 stood at ₹8.40 crore, up from ₹6.40 crore in the same period last year.
Nine-month (9M) Revenue increased to ₹813.12 crore compared to ₹730.23 crore in the previous year.
The company transitioned to a single operating and reportable segment named 'Chemicals' for better strategic focus.
An incremental provision of ₹115.42 lakhs was made for Gratuity following the notification of new Government Labour Codes.
👀 What to Watch
The quarterly recovery in profit and revenue growth is a positive signal, though the year-to-date profit decline warrants a cautious outlook on overall margin stability. Investors should monitor if the new single-segment focus improves operational efficiency in upcoming quarters.
Excel Industries Q3 FY26 Revenue Rises 19% to ₹233 Cr; PAT Up 31% YoY
Excel Industries reported a strong Q3 FY26 with revenue growing 19% YoY to ₹233 crore, driven by improved demand in performance solutions and better price realizations. While quarterly PAT rose 31% to ₹8 crore, the 9-month performance shows a cumulative decline in profitability with 9M PAT down 16% YoY to ₹61 crore. The company is planning a significant capital expenditure of ₹200-300 crore over the next three years for capacity expansion and technology upgrades. Export contributions remain steady, accounting for 27% of quarterly revenue.
Key Highlights
Q3 FY26 Revenue grew 19% YoY to ₹233 Cr, while Adjusted EBITDA rose 39% to ₹17 Cr.
9M FY26 Revenue increased 11% to ₹813 Cr, though PAT declined 16% to ₹61 Cr compared to the previous year.
Planned Capex of ₹200-300 Cr over the next 3 years for plant upgrades, product innovation, and capacity expansion.
Adjusted EBITDA margin for Q3 FY26 improved by 100bps YoY to 7.3% due to favorable product mix.
Export revenue contributed 27% to the total revenue in Q3 FY26, up from 22.3% for the 9-month period.
👀 What to Watch
Investors should monitor the execution of the ₹200-300 crore capex plan and the recovery in 9-month profitability margins. The strong quarterly growth in performance solutions and biocides suggests a positive turnaround in demand that needs to be sustained.
Excel Industries Approves Unaudited Financial Results for Q3 FY2025-26
Excel Industries Limited has officially approved its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors met on February 3, 2026, for over four and a half hours to review and finalize the performance metrics. The submission includes the statutory Limited Review Report, ensuring regulatory compliance under SEBI guidelines. While the cover letter does not disclose specific profit figures, it confirms the completion of the audit committee's review process.
Key Highlights
Board approved financial results for the quarter and nine months ended December 31, 2025.
The Board meeting lasted approximately 4 hours and 40 minutes, concluding at 06:40 p.m.
Results were reviewed and recommended by the Audit Committee prior to Board approval.
The filing includes the Limited Review Report issued by the company's statutory auditors.
The announcement covers both Chemicals and Environment & Biotech divisions.
👀 What to Watch
Investors should examine the detailed financial tables attached to the full report to evaluate margin performance in the chemical segment. Compare the year-on-year growth for the nine-month period ending December 2025 to assess the company's recovery or growth trajectory.
Excel Industries Approves Q3 FY26 Unaudited Financial Results
Excel Industries Limited's Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025, during their meeting on February 3, 2026. The results were reviewed and recommended by the Audit Committee prior to board approval. While the specific financial figures were not detailed in the cover letter, the announcement confirms the completion of the statutory review for the third quarter. The board meeting concluded at 6:40 p.m. following a nearly five-hour session.
Key Highlights
Board approved unaudited financial results for the quarter ended December 31, 2025.
Financial results for the nine-month period ending December 31, 2025, were also cleared.
The Audit Committee conducted a prior review and recommendation of the financials.
A Limited Review Report from the statutory auditors has been filed with the results.
The board meeting lasted approximately 4 hours and 40 minutes.
👀 What to Watch
Investors should closely examine the detailed financial tables and the Limited Review Report to evaluate the company's margin performance and revenue growth. Compare these results against industry peers in the chemicals and biotech sectors to assess relative performance.
